No Data
Sino Biopharmaceutical's Drug Study Shows 85.2% Failure-Free Survival Rate for 12 Months
Hong Kong Stock Announcement Gold Mining | SITC's annual profit attributable to shareholders is 1.028 billion US dollars, representing a year-on-year increase of 93.51%.
SINO BIOPHARM (01177): Global first JAK/ROCK inhibitor "Rovadicitinib" phase IB/IIA clinical research results published in "Blood"; SITC's annual shareholder attributable profit of 1.028 billion USD, a year-on-year increase of 93.51%...
SINO BIOPHARM (01177.HK): The global first JAK/ROCK inhibitor "ROVADICITINIB" phase IB/IIA clinical research results published in "Blood".
On March 10, Glonghui reported that SINO BIOPHARM (01177.HK) announced that the clinical research results of the self-developed national Class 1 Innovative Drug "Rovadicitinib" for the treatment of chronic graft-versus-host disease (cGVHD) in the Ib/IIa phase have been published in the top international hematology journal "Blood" (Blood, IF: 21.0). Rovadicitinib is the world's first oral small molecule inhibitor with a dual inhibition mechanism of both JAK and ROCK, targeting JAK1/2 and ROCK1/2, and has both anti-inflammatory and anti-fibrotic effects.
Morgan Stanley maintains a "Shareholding" rating for SINO BIOPHARM and raises the Target Price to 4.6 Hong Kong dollars.
Morgan Stanley released a Research Report stating that it maintains SINO BIOPHARM (01177) with a "Shareholding" rating, raising the Target Price from 4.5 HKD to 4.6 HKD. The bank has raised its net profit forecast for the company by 11%, mainly benefiting from Sinovac Biotech's dividend income of approximately 0.7 billion yuan. Due to slight adjustments in the sales cost forecast, net profits are expected to grow by 0.5% for both 2025 and 2026. Morgan Stanley's forecast for the company's sales in 2024 has been revised down by 1.2%, mainly due to weak sales of the pharmaceutical Ganmei under stricter healthcare insurance restrictions. Considering the Pertuzumab biosimilar.
[Brokerage Focus] Morgan Stanley maintains a "Shareholding" rating for SINO BIOPHARM (01177) and raises its net profit forecast.
Jinwu Finance | Morgan Stanley released a report, predicting a 1.2% decrease in SINO BIOPHARM (01177) sales for 2024, primarily due to the worsening sales performance of the pharmaceutical Ganmei under stricter healthcare insurance restrictions. Notably, as Pertuzumab biosimilars are expected to be approved in December 2024, and CDK2/4/6 will also be approved in 2025, based on this, Morgan Stanley expects SINO BIOPHARM's sales to grow by 2.2% and 3.7% in 2024 and 2025, respectively. On the profit side, Morgan Stanley raised the company's profit forecast by 11%, with the key reasons behind it.
National People's Congress representative, Zhao Jing of Shandong Buchang Pharmaceuticals: "The 'AI+' is reaching a critical point of explosion. It is recommended to utilize AI to empower the inheritance and innovation of Traditional Chinese Medicine | Two
① Zhao Jing, a representative of the National People's Congress and Vice Director of Shandong Buchang Pharmaceuticals, brought the proposal "Utilizing AI to Empower the Inheritance and Innovation of Traditional Chinese Medicine and Build a New Pattern of Development for Traditional Chinese Medicine with 'Asia Vets + Technology'" to this year's Two Sessions, aiming to promote the intelligent upgrade of the Traditional Chinese Medicine industry through AI technology. ② Zhao Jing stated that the development of large models like DeepSeek has indeed pushed the integration of Traditional Chinese Medicine and AI to a critical point of explosion.
